Pfizer Inc (PFE)
27.72
-0.22
(-0.79%)
USD |
NYSE |
Mar 18, 16:00
Pfizer Enterprise Value: 214.96B for March 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
March 18, 2024 | 214.96B |
March 15, 2024 | 216.20B |
March 14, 2024 | 217.27B |
March 13, 2024 | 217.78B |
March 12, 2024 | 216.60B |
March 11, 2024 | 218.63B |
March 08, 2024 | 212.13B |
March 07, 2024 | 209.71B |
March 06, 2024 | 211.96B |
March 05, 2024 | 205.70B |
March 04, 2024 | 204.62B |
March 01, 2024 | 208.58B |
February 29, 2024 | 208.41B |
February 28, 2024 | 211.12B |
February 27, 2024 | 210.27B |
February 26, 2024 | 211.91B |
February 23, 2024 | 215.18B |
February 22, 2024 | 214.00B |
February 21, 2024 | 214.68B |
February 20, 2024 | 214.22B |
February 16, 2024 | 214.39B |
February 15, 2024 | 213.77B |
February 14, 2024 | 211.49B |
February 13, 2024 | 210.70B |
February 12, 2024 | 214.60B |
Date | Value |
---|---|
February 09, 2024 | 214.03B |
February 08, 2024 | 214.09B |
February 07, 2024 | 214.03B |
February 06, 2024 | 213.69B |
February 05, 2024 | 208.44B |
February 02, 2024 | 210.48B |
February 01, 2024 | 212.51B |
January 31, 2024 | 211.32B |
January 30, 2024 | 210.98B |
January 29, 2024 | 213.58B |
January 26, 2024 | 213.52B |
January 25, 2024 | 213.52B |
January 24, 2024 | 218.38B |
January 23, 2024 | 218.94B |
January 22, 2024 | 218.27B |
January 19, 2024 | 218.10B |
January 18, 2024 | 217.03B |
January 17, 2024 | 217.36B |
January 16, 2024 | 218.32B |
January 12, 2024 | 220.47B |
January 11, 2024 | 218.78B |
January 10, 2024 | 222.11B |
January 09, 2024 | 224.42B |
January 08, 2024 | 225.44B |
January 05, 2024 | 224.82B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
167.23B
Minimum
Dec 14 2023
352.78B
Maximum
Dec 16 2021
248.76B
Average
244.87B
Median
Enterprise Value Benchmarks
Amgen Inc | 198.85B |
Gilead Sciences Inc | 108.90B |
Johnson & Johnson | 384.00B |
Eli Lilly and Co | 747.04B |
Moderna Inc | 31.23B |
Enterprise Value Related Metrics
Net Income (Quarterly) | -3.369B |
Revenue (Quarterly) | 14.25B |
Total Expenses (Quarterly) | 16.22B |
EPS Diluted (Quarterly) | -0.60 |
Gross Profit Margin (Quarterly) | 46.92% |
Profit Margin (Quarterly) | -23.64% |
Earnings Yield | 1.30% |
Operating Earnings Yield | 2.13% |
Normalized Earnings Yield | 3.840 |